Results 251 to 260 of about 222,938 (359)

Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice

Obesity, EarlyView.
ABSTRACT Objective This study aimed to characterize the reasons for treatment discontinuation with injectable semaglutide or tirzepatide for obesity in regular clinical practice. Methods This cross‐sectional study used electronic health record data between January 2022 and December 2024 from a single integrated health system in Ohio and Florida.
Hamlet Gasoyan, W. Scott Butsch, Nicholas J. Casacchia, Rebecca Schulte, Victoria Criswell, Jacqueline Fox, Holly Renner, Phuc Le, Jordan Alpert, Michael B. Rothberg   +9 more
wiley   +1 more source

Abnormal Glucagon Secretion Contributes to a Longitudinal Decline in Glucose Tolerance. [PDF]

J Clin Endocrinol Metab
Mohan S, Christie HE, Laurenti MC, Egan AM, Bailey KR, Cobelli C, Dalla Man C, Vella A.   +7 more
europepmc   +1 more source

Stem Cell Secretome Treatment Reduces Adiposity and Improves Glucose Handling During Obesity and Weight Loss in Mice

Obesity, EarlyView.
ABSTRACT Objective In this study, we investigated the effects of a stem cell‐derived secretome product on adiposity and tissue quality and insulin and glucose levels in obese mice and those undergoing dietary weight loss. Methods Following 16 weeks of high fat diet mice received acute (4 weeks) biweekly intramuscular injections with vehicle or ...
Zachary J. Fennel, Anu S. Kurian, Paul‐Emile Bourrant, Chad M. Skiles, Robert J. Castro, Elena M. Yee, Scott A. Greilach, Hans S. Keirstead, Gabriel Nistor, Nicole C. Berchtold, Thomas E. Lane, Micah J. Drummond   +11 more
wiley   +1 more source

Characterization of Cytokine Treatment on Human Pancreatic Islets by Top‐Down Proteomics

PROTEOMICS, EarlyView.
ABSTRACT Type 1 diabetes (T1D) results from autoimmune‐mediated destruction of insulin‐producing β cells in the pancreatic islet. This process is modulated by pro‐inflammatory cytokine signaling, which has been previously shown to alter protein expression in ex vivo islets.
Ashley N. Ives, Tyler J. Sagendorf, Lorenz Nierves, Tai‐Tu Lin, Ercument Dirice, Rohit N. Kulkarni, Ljiljana Paša‐Tolić, Wei‐Jun Qian, James M. Fulcher   +8 more
wiley   +1 more source

Genetically proxied glucagon-like peptide-1 receptor agonist is associated with risk of tubulo-interstitial nephritis: A network Mendelian randomization study. [PDF]

Medicine (Baltimore)
Xu XC, Huang FZ, Ying J, Zhang TT, Huang HY.   +4 more
europepmc   +1 more source

A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Dulaglutide, a long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for improving glycemic control and reducing cardiovascular risks in patients with type 2 diabetes mellitus (T2DM). This research investigates the effect of dulaglutide on gastric emptying and its impact on the pharmacokinetics (PK) of orally administered ...
Maria M. Posada, Karen B. Schneck, Bridget L. Morse, Luc R. A. Rougee, Lai San Tham, Jessica F. Rehmel, Brian Thompson, Stephen D. Stamatis, Stephen D. Hall, Gemma L. Dickinson   +9 more
wiley   +1 more source

Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. [PDF]

World J Gastroenterol
Concepción-Zavaleta MJ, Fuentes-Mendoza JM, Gonzáles-Yovera JG, Ruvalcaba-Barbosa GY, Cura-Rodríguez LD, González-Rodríguez JS, Concepción-Urteaga LA, Pérez-Reyes AI, Quiroz-Aldave JE, Paz-Ibarra J.   +9 more
europepmc   +1 more source

Sustained‐Release Sitagliptin Microneedles for Scar Prevention via Fibroblast‐to‐Adipocyte Conversion

Small Science, EarlyView.
The authors propose a novel use for the conventional hypoglycemic drug, dipeptidyl peptidase IV (DPP4+) inhibitor sitagliptin. Sitagliptin prevents scar formation during wound healing through fibroblast‐to‐adipocyte conversion at least by preventing DPP4‐mediated truncation of IGF‐1.
Ju‐Lei Zhang, Jun‐Nian Zhou, Chao Tang, Yan Li, Wen‐De Yao, Ling‐Li Guo, Zhao‐Yang Chen, Ya‐Li Jia, Quan Zeng, Biao Zhang, Tao Fan, Jia‐Fei Xi, Xue‐Tao Pei, Yan Han, Wen Yue   +14 more
wiley   +1 more source

Improved cardiovascular outcomes with glucagon-like peptide-1 receptor agonists - what is the role of weight reduction? [PDF]

Cardiovasc Endocrinol Metab
Jacob S, Eckel RH, Krentz AJ.
europepmc   +1 more source

Influence of glucagon on pancreatic exocrine secretion.

, 1969
Walter P. Dyck, J Rudick, Barton Hoexter, Henry D. Janowitz   +3 more
openalex